Merck & Co. (MRK) : First Dallas Securities scooped up 301 additional shares in Merck & Co. during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 26, 2016. The investment management firm now holds a total of 13,777 shares of Merck & Co. which is valued at $807,332.Merck & Co. makes up approximately 0.60% of First Dallas Securities’s portfolio.
Other Hedge Funds, Including , Pggm Investments boosted its stake in MRK in the latest quarter, The investment management firm added 156,975 additional shares and now holds a total of 4,599,914 shares of Merck & Co. which is valued at $269,554,960. Merck & Co. makes up approx 1.34% of Pggm Investments’s portfolio.Country Club Trust Company N.a. boosted its stake in MRK in the latest quarter, The investment management firm added 5,202 additional shares and now holds a total of 134,265 shares of Merck & Co. which is valued at $7,897,467. Merck & Co. makes up approx 1.11% of Country Club Trust Company N.a.’s portfolio.Hartford Financial Management reduced its stake in MRK by selling 150 shares or 0.52% in the most recent quarter. The Hedge Fund company now holds 28,599 shares of MRK which is valued at $1,705,358. Merck & Co. makes up approx 0.99% of Hartford Financial Management’s portfolio.North Star Investment Management Corp. reduced its stake in MRK by selling 438 shares or 0.68% in the most recent quarter. The Hedge Fund company now holds 64,289 shares of MRK which is valued at $3,828,410. Merck & Co. makes up approx 0.69% of North Star Investment Management Corp.’s portfolio.Nadler Financial Group boosted its stake in MRK in the latest quarter, The investment management firm added 7 additional shares and now holds a total of 9,747 shares of Merck & Co. which is valued at $578,484. Merck & Co. makes up approx 0.24% of Nadler Financial Group’s portfolio.
Merck & Co. opened for trading at $59.01 and hit $59.2 on the upside on Friday, eventually ending the session at $58.66, with a gain of 0.39% or 0.23 points. The heightened volatility saw the trading volume jump to 84,91,237 shares. Company has a market cap of $162,372 M.
On the company’s financial health, Merck & Co. reported $0.93 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $0.91. The company had revenue of $9844.00 million for the quarter, compared to analysts expectations of $9782.80 million. The company’s revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.86 EPS.
Investors should note that on Jul 26, 2016, Merck & Co. announced a cash dividend of $0.4600. The company’s management has announced Sep 13, 2016 as the ex-dividend date and fixed the record date on Sep 15, 2016. The payable date has been fixed on Oct 7, 2016.
Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Companys animal health products are sold to veterinarians distributors and animal producers.